secwatch.observer — SEC 8-K summary
======================================

Issuer:     PUMA BIOTECHNOLOGY, INC. (PBYI)
CIK:        0001401667
Form:       8-K
Filed at:   2023-08-18T23:59:59+00:00
Accession:  0001437749-23-024168
Event type: other
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Puma Biotechnology amends bylaws to align with universal proxy rules and enhance stockholder disclosure requirements
--------------------------------------------------------------------------------

- Board adopted Fourth Amended and Restated Bylaws on August 17, 2023, effective immediately.
- Amendments address universal proxy rules under Rule 14a-19, requiring compliance for non-board solicitations.
- Non-board proxy solicitations must use a proxy card color other than white, reserved for Board use.
- Enhanced advance notice disclosure for stockholders proposing business or nominating directors, including ownership and litigation info.
- Technical updates to align with Delaware General Corporation Law and Exchange Act.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401667/000143774923024168/0001437749-23-024168-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401667/000143774923024168/pbyi20230817_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-024168

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer